PMID- 37777375
OWN - NLM
STAT- MEDLINE
DCOM- 20240116
LR  - 20240416
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 45
IP  - 12
DP  - 2023 Dec
TI  - Dorzagliatin for Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis 
      of Randomized Phase II/III Trials.
PG  - 1277-1283
LID - S0149-2918(23)00356-9 [pii]
LID - 10.1016/j.clinthera.2023.09.011 [doi]
AB  - PURPOSE: Dorzagliatin is a glucokinase agonist with effects on type 2 diabetes 
      mellitus (T2DM). This study included a meta-analysis on the efficacy and safety 
      of dorzagliatin in the treatment of T2DM. METHODS: The Cochrane Central Registry 
      of Controlled Trials, PubMed, and Embase were searched from inception to July 25, 
      2022. A total of 3 studies including 1333 patients were identified in this 
      meta-analysis. FINDINGS: Overall, the meta-analysis showed that dorzagliatin 
      remarkably reduced glycated hemoglobin levels versus placebo by 0.66%. The 
      results of the meta-analysis showed a significant reduction in fasting plasma 
      glucose of 6.77 mg/dL between dorzagliatin and placebo. In addition, dorzagliatin 
      reduced 2-hour postprandial glucose (2h-PPG) by 43.87 mg/dL compared with 
      placebo. Furthermore, the meta-analysis of available data revealed a significant 
      reduction in the Homeostasis Model Assessment of Insulin Resistance of 0.07 
      between dorzagliatin and placebo. The risk of adverse events was slightly higher 
      with dorzagliatin than with placebo. IMPLICATIONS: Dorzagliatin significantly 
      reduced glycated hemoglobin levels, fasting plasma glucose levels, 2h-PPG, and 
      homeostasis model assessment 2 of insulin resistance in patients with T2DM. It 
      was well tolerated and had good liver and kidney safety profiles.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, Sichuan, China; Clinical Medical College, Chengdu Medical College, 
      Chengdu, Sichuan, China.
FAU - He, Rong
AU  - He R
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, Sichuan, China; Clinical Medical 
      College, Chengdu Medical College, Chengdu, Sichuan, China.
FAU - Ling, Baodong
AU  - Ling B
AD  - School of Pharmacy, Chengdu Medical College, Chengdu, China.
FAU - Wang, Lin
AU  - Wang L
AD  - Department of Pharmacy, Sichuan Mianyang 404 Hospital, Mianyang, Sichuan, China.
FAU - Jiang, Ting
AU  - Jiang T
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, Sichuan, China; Clinical Medical College, Chengdu Medical College, 
      Chengdu, Sichuan, China.
FAU - Yu, Bin
AU  - Yu B
AD  - Department of Pharmacy, Mianyang Central Hospital, Mianyang, China; School of 
      Medicine, University of Electronic Science and Technology of China, Mianyang, 
      Sichuan, China. Electronic address: medicine2134@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230929
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Blood Glucose)
RN  - X59W6980E8 (Dorzagliatin)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - Blood Glucose
MH  - Clinical Trials, Phase II as Topic
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin
MH  - Hypoglycemic Agents/adverse effects
MH  - *Insulin Resistance
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Dorzagliatin
OT  - Efficacy
OT  - Glucokinase agonists
OT  - Systematic review
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interest None declared.
EDAT- 2023/10/01 04:44
MHDA- 2023/12/17 09:42
CRDT- 2023/09/30 21:54
PHST- 2023/04/05 00:00 [received]
PHST- 2023/06/27 00:00 [revised]
PHST- 2023/09/13 00:00 [accepted]
PHST- 2023/12/17 09:42 [medline]
PHST- 2023/10/01 04:44 [pubmed]
PHST- 2023/09/30 21:54 [entrez]
AID - S0149-2918(23)00356-9 [pii]
AID - 10.1016/j.clinthera.2023.09.011 [doi]
PST - ppublish
SO  - Clin Ther. 2023 Dec;45(12):1277-1283. doi: 10.1016/j.clinthera.2023.09.011. Epub 
      2023 Sep 29.